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ABSTRACT 
Background: A variant (rs3812316, C771G, Gln241His) in the MLXIPL (Max-like 
protein X interacting protein-like) gene encoding the carbohydrate response element 
binding protein has been associated with lower triglycerides. However, its association 
with cardiovascular diseases and gene-diet interactions modulating these traits are 
unknown. 
Methods and Results: We studied 7,166 participants in the PREDIMED trial testing a 
Mediterranean diet (MedDiet) intervention versus a control diet for cardiovascular 
prevention, with a median follow-up of 4.8 years. Diet, lipids, MLXIPL 
polymorphisms and cardiovascular events were assessed. Data were analyzed at 
baseline and longitudinally. We used multivariable-adjusted Cox regression to estimate 
hazard ratios (HR) for cardiovascular outcomes. The MLXIPL-rs3812316 was 
associated with lower baseline triglycerides (P=5.5x10-5) and lower 
hypertriglyceridemia (odds ratio [OR]: 0.73; 95%CI, 0.63-0.85; P=1.4x10-6 in G-
carriers versus CC). This association was modulated by baseline adherence to MedDiet 
(AdMedDiet). When AdMedDiet was high, the protection was stronger (OR: 0.63, 
95%CI: 0.51-0.77; P=8.6x10-6) than when AdMedDiet was low (OR: 0.88, 95%CI: 
0.70-1.09;P=0.219). Throughout the follow-up, both the MLXIPL-rs3812316 
(P=3.8x10-6) and the MedDiet intervention (P=0.030) were significantly associated 
with decreased triglycerides. Likewise in G-carriers MedDiet intervention was 
associated with greater total cardiovascular risk reduction and specifically for 
myocardial infarction. In the MedDiet, but not in the control group, we observed lower 
myocardial infarction incidence in G-carriers versus CC (HR: 0.34; 95%CI:0.12-
0.93;P=0.036 and 0.90; 95%CI: 0.35-2.33;P=0.830, respectively). 
Conclusion: Our novel results suggest that MedDiet enhances the triglyceride-
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lowering effect of the MLXIPL-rs3812316 variant and strengthens its protective effect 
on myocardial infarction incidence. 
Clinical Trial Registration: http://www.controlled-trials.com/; number, 
ISRCTN35739639. 
 
Key Words: Gene-diet interactions, Mediterranean diet, cardiovascular disease, 
myocardial infarction. 
 
 5
Given that hypertriglyceridemia is re-emerging as an important cardiovascular 
disease risk factor1-3, it is essential to gain further understanding about the genes 
involved and the environmental factors that modulate their expression4,5. Outstanding 
among the genes that have recently been associated with triglyceride metabolism is the 
MLXIPL (Max-like protein X interacting protein-like, also known as Mondo B) that 
encodes the carbohydrate response element binding protein (CHREBP). In a genome-
wide association study (GWAs)6, we and others reported for the first time that the 
MLXIPL was a new locus associated with plasma triglycerides. We found that the 
minor allele of the intergenic rs17145738 polymorphism, located downstream of 
MLXIPL, was associated with significantly lower plasma triglyceride concentrations6. 
This observation was in line with previous work in animal models in which the 
ChREBP, discovered by the group of Uyeda7, was characterized as an important 
transcription factor coupling hepatic glucose utilization and lipogenesis8. Subsequent 
studies in animal models confirmed the crucial role of ChREBP in regulating the 
process that converts excess of dietary carbohydrate into triglycerides and suggested its 
implication in the development of the metabolic syndrome9,10. However, given the 
intergenic location of the rs17145738 polymorphism between the MLXIPL/TBL2 
genes6, the direct involvement of this gene in human triglyceride metabolism was not 
consolidated until Kooner et al11 identified a functional variant (rs3812316, C771G, 
amino acid change Gln241His), located in an evolutionarily conserved region encoding 
a domain implicated in the activation of MLXIPL10. In view of the association of the 
minor G allele with low triglyceride concentrations, the authors suggested a reduced 
MLXIPL function for this variant, consistent with the low triglycerides described in 
Chrebp-deficient mice9,12. 
The two variants rs17145738 and rs3812316 are in high linkage disequilibrium 
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(LD), so explaining our previous results6. However, the existing literature provides a 
more heterogeneous perspective6,11,13-21. Although the GWAs and meta-analyses have 
consistently found a significant association between the minor allele and lower 
triglyceride concentrations6,11,13,14, other experimental approaches have not shown the 
same consistency18-21 which may be due to the fact that the expression of this gene and 
its biological consequences have been shown to be strongly modulated by diet (i.e., 
total fat, polyunsaturated fatty acids, total carbohydrates, or fructose)7,8,12,22,23. Thus, 
unexplored gene-diet interactions might be affecting the outcomes of human studies. 
Similarly, the association between MLXIPL polymorphisms and cardiovascular 
diseases is also heterogeneous. Although two studies on Chinese subjects24, 25 reported 
significant associations between MLXIPL polymorphisms and lower risk of coronary 
artery disease, such an association has not been supported in meta-analyses13,26. 
Therefore, the aims of the present study were: 1) to assess the impact of the MLXIPL-
rs3812316 polymorphism on triglyceride concentrations as well as the modulating 
effects of the Mediterranean diet (MedDiet) at baseline and longitudinally; 2) to study 
the association between this polymorphism and major cardiovascular events 
(myocardial infarction and stroke incidence), as well as its modulation through long-
term intervention (mean ≈5 years) with MedDiet; and 3) To analyze whether the 
effects of the MedDiet intervention on cardiovascular events is modulated by the 
MLXPIL-rs3812316 polymorphism. 
 
METHODS 
Detailed Methods are included in the Supplement. 
Subjects 
We studied 7,161 participants (3,049 men and 4,112 women) in the PREDIMED 
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(PREvención with DIeta MEDiterránea) trial (27) from whom DNA was available and 
the MLXIPL-rs3812316 determined. The PREDIMED is a multi-center, randomized, 
controlled clinical trial (controlled-trials.com number, ISRCTN35739639) aimed at 
assessing the effects of the MedDiet on the primary prevention of cardiovascular 
disease27,28. The completion date of this study was December 2010 and the total number 
of randomized subjects was 7,447. The 7,166 participants included did not differ in the 
main characteristics from those of the total cohort. From October 2003 physicians in 
Primary Care Centers selected potential high cardiovascular risk subjects (Detailed in 
the Supplement). Participants were randomly assigned to these interventions: MedDiet 
with extra-virgin olive oil (EVOO), MeDiet with mixed nuts and control group (low-fat 
diet). Participants assigned to both MedDiet groups received intensive training to follow 
the MedDiet and allotments of either extra virgin olive oil or mixed nuts (30 g/d)27,28. 
Participants assigned to the control diet received recommendations to reduce the intake 
of all types of fat27. Participants were followed for a median of 4.8 years (interquartile 
range, 2.8 to 5.8 years). 
 
Demographic, clinical, anthropometric and dietary measurements 
The baseline examination included assessment of standard cardiovascular risk 
factors, medication use, socio-demographic factors and lifestyle variables27,28. The level 
of adherence to the MedDiet (AdMedDiet) was measured by a validated 14-item 
questionnaire29. It consisted of 14 questions on food consumption frequency and habits 
characteristic of the MedDiet (Supplemental Table 1). Each question was scored 0 or 
1. 
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Outcome ascertainment 
The primary endpoint was the occurrence of the first major cardiovascular event 
and comprised myocardial infarction, stroke or cardiovascular death as detailed in the 
Supplement and elsewhere27. End-points confirmed by the committee occurring 
between October 1, 2003, and December 1, 2010 were included in the analyses. 
 
Biochemical determinations, DNA extraction and genotyping 
Blood samples were obtained after an overnight fast and were frozen at -80ºC. 
Fasting glucose, total cholesterol, triglycerides, HDL-C and LDL-C were measured 
using standard enzymatic methods28. 
Genomic DNA was extracted from buffy-coat. We genotyped the intergenic 
MLXIPL-rs17145738 (in a sub-sample consisting of 1016 participants recruited in the 
Valencia region) and the nonsynonymous (Gln241His) rs3812316 polymorphism (in the 
whole sample) on a 7900HT Sequence Detection System (Applied Biosystems, Foster 
City, CA, USA) using a fluorescent allelic discrimination TaqManTM assay with a 
calling rate >95%. 5% of samples were randomly selected and genotyped a second time 
and no discrepancies were found. Genotype frequencies did not deviate from Hardy-
Weinberg equilibrium expectations (P=0.069 for the rs17145738 and P= 0.187 for the 
rs3812316). We found strong linkage disequilibrium (LD) between both polymorphisms 
(D’: 0.955; r2: 0.895; P<0.001). Consistent with our previous findings6, the intergenic 
rs17145738 polymorphism was significantly associated with fasting triglycerides: 
1.52+/-0.93 mmol/L in CC vs. 1.34+/-0.77 mmol/L in T carriers; P=0.004, and we 
decided to continue the main study with the functional MLXIPL-rs3812316 
polymorphism. 
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Statistical Analyses 
LD was assessed with the Haploview software package. Chi-square tests were 
used to test differences in percentages. Triglycerides were log-transformed for the 
statistical analyses. Hypertriglyceridemia was defined as a fasting triglyceride level 
>1.7 mmol/l. MLXIPL polymorphisms were first tested as additive and further, carriers 
of the variant allele were grouped together (dominant model) due to the low prevalence 
of the variant allele. To compare crude means we applied t and ANOVA tests. 
Multivariable adjustments for continuous variables were carried out by covariance 
analysis. The control for possible confounders has been undertaken sequentially 
following the PREDIMED study general protocol. Firstly the models were adjusted for 
basic potential confounders such as age, gender and recruitment center (adding the 
adjustment for dietary intervention in the longitudinal studies to that basic model). 
Afterwards an additional control for more potential confounders such as BMI, type 2 
diabetes, medications (lipid-lowering and hypoglycemic drugs), alcohol consumption, 
physical activity, AdMedDiet at baseline, total energy intake, blood pressure, family 
history of cardiovascular disease, waist circumference or plasma lipids as specifically 
indicated in the corresponding analyses. The aim of this adjustment was to check 
whether, following the additional adjustments, the estimations of the polymorphism 
remained statistically significant or not. 
Dichotomous variables for AdMedDiet at baseline and physical activity were 
created using the sample means as cut-off. Logistic regression methods were also used 
to estimate the contribution of the polymorphism to predict hypertriglyceridemia at 
baseline. The interaction between the MLXIPL-rs3812316 polymorphism and 
AdMedDiet at baseline in determining triglycerides was tested in multivariable 
regression models (lineal or logistic) including the corresponding main effects and 
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interaction terms. Stratified analyses were also carried out. 
The longitudinal influence of the MLXIPL-rs3812316 polymorphism and dietary 
intervention (MedDiet groups were pooled versus the control group) on plasma 
triglyceride concentrations was analyzed by multivariable-ANOVA of repeated 
measures including those subjects having complete triglyceride data at baseline, 1, 3 
and 5 years (n=2,418 subjects). Recruitment of participants lasted from 2003 to 2009; 
therefore, some participants had not completed three or five years of follow-up by the 
1st December, 2010 study closing date. We also analyzed prevalence of 
hypertriglyceridemia by genotype and dietary intervention (MedDiet versus control) in 
the follow-up by logistic regression. To examine the association between intervention 
with MedDiet and cardiovascular events in all subjects (n=7,166), we used Cox 
regression models with the length of follow-up as the primary time variable. The 
exposure time was calculated as the time between randomization and the date of a major 
cardiovascular event, the date of the last interview, December 1st 2010, or the date at 
death, whichever came first. We evaluated both the association between the MLXIPL-
rs3812316 polymorphism and cardiovascular events depending on the dietary 
intervention in which hazard ratios (HR) with 95 % confidence intervals (CI) for the 
MLXIPL-rs3812316 polymorphism, stratified by intervention with MedDiet versus 
control group were calculated, as well as the effect of the dietary intervention with 
MedDiet during follow-up on major cardiovascular events depending on the MLXIPL-
rs3812316 polymorphism. In this case, HR and 95% CI for the MedDiet intervention 
were stratified by the polymorphism. We also analyzed the influence of baseline 
triglyceride concentrations on cardiovascular events in the Cox regression models. 
Analyses were based on the intention-to-treat principle. In multivariable model 1 (basic 
model) we adjusted for sex, age, center and intervention group. Multivariable models 2 
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and 3 included additional adjustments as detailed. Kaplan-Meier survival curves were 
plotted to estimate the probability of remaining free of myocardial infarction during 
follow-up. Statistical analyses were performed with the IBM SPSS Statistics version 
21.0, NY. All tests were two-tailed and p values <0.05 were considered statistically 
significant. 
 
RESULTS 
Prevalence of the MLXIPL-rs3812316 (C>G, Gln241His) genotypes were: 
83.2% CC, 15.4% CG, and 0.9% GG. Table 1 shows baseline demographic, 
biochemical, clinical and lifestyle characteristics of the 7,166 participants by the 
MLXIPL-rs3812316 polymorphism. There were no significant differences in sex, age, 
BMI, dietary intake, smoking, drinking, physical activity, type 2 diabetes, hypertension, 
or treatment with lipid lowering drugs between genotypes. Likewise, we found no 
significant differences of genotype distribution among intervention groups (MedDiet 
groups or control diet). Characteristics of the study participants according to the 
randomly assigned dietary intervention groups at baseline are shown in Supplemental 
Table 2. 
 
Baseline association between the MLXIPL-rs3812316 polymorphism and plasma lipid 
concentrations and fasting glucose and type 2 diabetes 
We observed (Table 2) a strong association between this polymorphism and 
lower triglyceride concentrations [B: -0.11 mmol/l (-9.86 mg/dl) per variant G-allele, 
95% CI: -0.17, -0.06; P=5.5x10-5] in the entire population. This association remained 
statistically significant after multivariable adjustment for potential confounders (models 
3 and 4, Table 2). We also found a protective effect (OR: 0.73; 95%CI: 0.63-0.85) 
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against hypertriglyceridemia (triglycerides>1.7 mmol/l), for carriers of the minor G-
allele in comparison with CC homozygotes. Moreover, we detected a significant 
association with fasting glucose that was higher in GG homozygous subjects, but the 
effect did not show a linear trend. In a recessive model, we observed a statistically 
significant association (P=0.014) between the polymorphism and type 2 diabetes. 
Homozygous subjects for the G-allele had lower type 2 diabetes risk in comparison with 
CC (OR: 0.52; 95%CI: 0.30-0.89). This association remained statistically significant 
after further multivariate adjustment (OR: 0.55; 95%CI: 0-32-0.95; P=0.033). 
 
Baseline modulation of the associations between the MLXIPL-rs3812316 
polymorphism and risk of hypertriglyceridemia by AdMedDiet 
We found a statistically significant gene-diet interaction between the MLXIPL-
rs3812316 polymorphism and baseline AdMedDiet on hypertriglyceridemia (P-
interaction: 0.025, which remained statistically significant after multivariate 
adjustment). When AdMedDiet was high (≥9 points), the protective effect of the variant 
allele against hypertriglyceridemia was stronger (OR: 0.63, 95% CI: 0.51-0.77; 
P=8.6x10-6). When AdMedDiet was low, the protection was attenuated and did not 
reach statistical significance (OR: 0.88, 95% CI: 0.70-1.09; P=0.219). These results 
remained consistent in a sensitivity analysis testing this gene-diet interaction in different 
sub-groups: men, women, type 2 diabetic and non-diabetic subjects (Table 3). We also 
observed a similar dietary modulation when plasma triglyceride concentrations at 
baseline were considered as a continuous variable (Supplemental Figure 1). 
 
Association between the MLXIPL-rs3812316 polymorphism and plasma triglycerides 
in the follow-up and modulation by the MedDiet 
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We analyzed the effect of this polymorphism on on-trial triglyceride 
concentrations (evolution of triglyceride levels over time) as well as the dietary 
modulation of this effect using longitudinal data from 5-year follow-up for all subjects 
having triglycerides measured at baseline, at 1-y, at 3-y and at 5-years (n=2,418 
subjects) in a model for repeated measures. In a model adjusted for dietary intervention 
and other covariables (Figure 1 A), we found a strong longitudinal association of the 
polymorphism and triglycerides (P=0.000004) with carriers of the variant allele having 
lower triglycerides. This association remained statistically significant at each time-
point. We also detected a statistically significant effect of the intervention with MedDiet 
on decreasing triglyceride concentrations in comparison with the control group 
(P=0.030 in the multivariable adjusted model) (Figure 1B). Although we did not find a 
statistically significant interaction between the MLXIPL-rs3812316 polymorphism and 
the dietary intervention through the follow-up (P=0.803), we observed a “biological 
interaction” by which G-allele carriers had lower triglyceride concentrations in the 
MedDiet intervention group than in the control group (Supplemental Figure 2). This 
effect was similar for hypertriglyceridemia (Supplemental Figure 3). Thus, in the 
multivariate adjusted model we found that after 5-years follow-up, G-carriers that 
received intervention with MedDiet had a significantly lower hypertriglyceridemia risk 
(OR: 0.62; 95%CI: 0.44-0.86; P=0.005 compared with CC subjects in the control 
group). However, consistent with our observation at baseline, G-carriers in the control 
group had an attenuated protection against hypertriglyceridemia risk (OR: 0.74; 95%CI: 
0.46-1.19; P=0.208 compared with CC subjects in the control group). 
 
Effects of dietary interventions on the associations between the MLXIPL-rs3812316 
polymorphism and incidence of cardiovascular diseases 
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After a median follow-up of 4.8 years (interquartile range, 2.8 to 5.8 years), 265 
major cardiovascular events occurred among the 7,166 participants (30,936 person-
years of observation). Of these, 99 were myocardial infarctions, 133 strokes and the 
other were cardiovascular deaths. Taking the population as a whole we observed no 
significant associations between the MLXIPL-rs3812316 polymorphism and total 
cardiovascular events (HR: 0.88; 95%CI:0.63-1.24; P=0.472 for G-carriers versus CC in 
a model adjusted for sex, age, center and dietary intervention group. Similar results 
were obtained after additional adjustments (not shown). However, the association 
between the MLXIPL-rs3812316 polymorphism and reduced incidence of myocardial 
infarction tended toward significance (HR: 0.53; 95%CI: 0.27-1.05; P=0.070 for G-
carriers versus CC) in the model adjusted for sex, age, center and dietary intervention. 
This result was similar in the fully adjusted model (HR: 0.51; 95%CI: 0.26-1.02; 
P=0.058). However, when studying cardiovascular events in the stratified analyses 
taking dietary intervention with MedDiet versus the control group into account, we 
obtained statistically significant results. Table 4 presents the HRs for the incidence of 
cardiovascular events (total, myocardial infarction and stroke) for the MLXIPL-
rs3812316 genotypes according to the dietary intervention groups (control group and 
MedDiet). We found that G-carriers had a significantly lower risk of myocardial 
infarction than CC homozygotes in the MedDiet intervention group (HR: 0.34; 95%CI: 
0.12-0.93; P=0.036, in the model adjusted for sex, age, center, and dietary intervention). 
No significant association was found in the control group (HR: 0.90; 95%CI: 0.35-2.33; 
P=0.830). Results were similar after additional multivariable adjustment (Table 4). No 
statistically significant dietary modulations were found for stroke. 
 
Effects of the MLXIPL-rs3812316 polymorphism on the association between the 
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intervention with MedDiet and incidence of cardiovascular diseases 
We examined the effect of the dietary intervention (MedDiet versus control) by 
genotype on cardiovascular events and found (Supplemental Table 3) that the MedDiet 
intervention appears to be more efficacious among G-allele carriers. Thus, we obtained 
a statistically higher risk reduction for total cardiovascular diseases in G-carriers (HR: 
0.51; 95%CI:0.26-0.99; P=0.045 for the MedDiet intervention group versus control) 
than in CC homozygotes (HR: 0.69; 95%CI: 0.52-0.91; P=0.008) in the adjusted 
models. A similar not statistically significant trend was found for stroke. Nevertheless, 
we observed a statistically significant risk reduction of the MedDiet vs control for 
myocardial infarction in G-allele carriers (HR: 0.24; 95%CI: 0.06-0.96; P=0.043) in 
comparison with the effect observed in CC (HR: 0.84; 95%CI:0.54-1.31; P=0.447). 
After further adjustment of these results for other covariables (hypertension, family 
history or cardiovascular disease, waist circumference and total cholesterol) or baseline 
hypertriglyceridemia, the association between the polymorphism and lower risk of 
myocardial infarction in the MedDiet intervention group remained statistically 
significant (P<0.05). In these Cox-multivariable models, baseline hypertiglyceridemia 
was significantly associated with higher risk of cardiovascular diseases, myocardial 
infarction and stroke in the whole population (all P<0.01). For myocardial infarction, 
we also expressed the relative risks from Cox regression with a single referent group 
(controls with CC - and the other 3 groups referent to that) as well as the incidence rates 
in Supplemental Table 4. 
 
DISCUSSION 
In this dietary intervention study, conducted in a large cohort of high 
cardiovascular risk subjects we found that the MLXIPL-rs3812316 polymorphism was a 
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strong genetic determinant of fasting triglycerides and hypertriglyceridemia both at 
baseline and in the follow-up. Carriers of the variant G-allele presented lower 
triglyceride concentrations in comparison with homozygous subjects for the common 
allele, consistent with previous reports at cross-sectional level for either the rs3812316 
or for the intergenic rs17145738 polymorphism6,12-17, 30-32, and added new longitudinal 
evidence for this association after 5-years follow-up. Moreover, we provide novel 
evidence supporting the fact that AdMedDiet can modulate the effects of the MLXIPL-
rs3812316 polymorphism in determining plasma triglyceride concentrations. Thus, 
when AdMedDiet was low (below the population mean), the genetic effect of the G-
allele reducing fasting triglyceride concentrations was attenuated and, when AdMedDiet 
was high (above the population mean), the decreasing effect of the G-allele on 
triglyceride concentrations was magnified. This cross-sectional observation at baseline 
was reinforced by the results of the longitudinal analysis showing a “biological” 
interaction with the intervention with MedDiet. Although intervention with MedDiet 
decreased triglyceride concentrations in both CC and G-allele carriers in comparison 
with the control group, G-allele carriers had lower triglyceride concentrations and a 
statistically significant lower risk of hypertriglyceridemia in a MedDiet intervention 
than in a low-fat control diet, so modifying the potential genetic determinism. 
In addition to the differences in linkage disequilibrium between the several 
variants in different populations, the observed gene-diet interaction may help explain 
some ethnic- and population-specific associations described for the MLXIPL 
polymorphisms with triglycerides in different settings and dietary intakes6,11-21,30-32. 
Thus, Musunuru et al32 observed that the MLXIPL polymorphisms were strongly 
associated with triglycerides in European American populations (P<0.001), but they 
failed to find significant associations in African Americans. Also, inter-population 
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specific differences were noted in the multiethnic United States National Health and 
Nutrition Examination Survey III18. In the present study we focused on the overall 
dietary pattern by analyzing the level of adherence to the MedDiet at baseline (or 
MedDiet intervention in the follow-up), a healthy dietary pattern characterized by a high 
intake of vegetables, fruits, cereals, olive oil, fish, legumes, and nuts that is low in 
saturated fats and simple carbohydrates and rich in MUFA and fiber27. As far as we 
know, ours is the first study to report a gene-diet interaction between MLXIPL-
rs3812316 polymorphism and AdMedDiet on plasma triglycerides in humans. However, 
although the detailed regulation of ChREBP remains unknown, several studies in 
animal models have reported that diet modulates ChREBP gene expression as well as 
the effects on triglyceride and carbohydrate metabolism7,8,22,23,33,34, so supporting our 
results. In the first murine ChREBP-knockout model8 it was observed that ChREBP 
deficiency caused intolerance of simple carbohydrates (60% glucose or sucrose) and 
although ChREBP -/- mice were viable and appear to have a normal life span on a 
standard diet, when ChREBP-knockout mice were fed with a high-fructose (70%) diet 
they died within a few days. In addition to this extreme gene-diet interaction the authors 
also observed differences in liver triglycerides, glucose and other metabolites when 
ChREBP-knockout mice fed with a standard diet (standard rodent chow, Harlan Teklad 
Mouse/Rat Diet 7002) were compared with ChREBP-knockout mice fed with a high-
starch diet (60% starch, 20% casein, 15% cellulose, 2.5% vitamins, and 2.5% minerals) 
and the statistical differences with wild-type mice were analyzed8. However, no 
significant effect on plasma triglycerides was detected8. The effect the ChREBP 
deficiency on reduced plasma triglycerides was more clearly observed in another work 
using a ChREBP-null ob/ob murine model12, in which a normalization of plasma 
triglyceride levels was detected in comparison to the high triglycerides found in ob/ob 
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mice. Erion et al33, using a murine model in which expression of ChREBP was 
decreased with a specific antisense oligonucleotide, also observed a reduction of plasma 
triglycerides. As suggested by others11, the amino acid change caused by the MLXIPL-
rs3812316 polymorphism could be related with a lower CHERBP activity in humans 
mimicking the phenotypes observed in deficient murine models. Moreover Erion et al33 
compared the effect of high-safflower oil versus a high-fructose diet on plasma 
triglycerides in the ChREBP deficient mice and observed lower levels in the high-fat 
than in the high-fructose group. Our results in humans showing lower triglyceride 
concentrations in G-carriers when consuming a high-MUFA MedDiet are in agreement 
with this observation. Likewise, Dentin et al22 demonstrated in mice that PUFA 
suppressed ChREBP activity. However, additional work is needed both to better 
characterize the mechanisms involved and to specifically analyze the components of the 
MedDiet (high MUFA, fiber intake, PUFA, low saturated fat, etc.) responsible for the 
observed gene-diet interaction on triglyceride concentrations. 
Furthermore, silencing of ChREBP in ob/ob mice9 has been associated with 
improvements in fasting glucose and insulin tolerance. In line with this observation, we 
have described here a novel association between the MLXIPL-rs3812316 polymorphism 
and lower type 2 diabetes risk in humans (recessive model). Although the ChREBP is 
now considered a key player in insulin resistance10,33,34, there are still paradoxical 
results regarding underexpression or overexpression of this gene depending on the liver 
or the adipose tissue associated with this phenotype. 
Another novel and important finding from our study is the modulation by the 
MedDiet of the association between the MLXIPL-rs3812316 polymorphism and incident 
myocardial infarction. Few studies have analyzed the association between the MLXIPL-
rs3812316 polymorphism and cardiovascular diseases, and their results have been 
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inconsistent13,24-26,31,35 probably because dietary modulation was not taken into 
consideration. Thus, while some24,25 reported a significant lower risk of coronary artery 
disease in carriers of the minor allele; the results of large meta-analyses (including 
several populations and more heterogeneity) did not confirm these findings13,26,31,35. The 
protective effect of the MLXIPL-rs3812316 polymorphism on myocardial infarction can 
be partially explained by the interaction of MedDiet on triglycerides, but other 
mechanisms are probably involved. Thus, the MLXIPL locus has also been associated 
with VLDL particle size and concentrations30, coagulation Factor VII levels36 and 
plasma concentrations of liver enzymes37. 
 
In conclusion, we reported three novel findings on the relationships of the 
nonsynonymous MLXIPL-rs3812316 polymorphism with cardiometabolic outcomes. 
First, in addition to triglyceride concentrations, we observed a lower risk of type 2 
diabetes in homozygous subjects for the variant G-allele. Second, its association with 
fasting triglycerides was modulated by AdMedDiet at baseline, the protective effect of 
the variant G-allele against hypertriglyceridemia being stronger when AdMedDiet was 
high. The results obtained in the intervention study reinforced these findings. Third, 
intervention with MedDiet increased the beneficial effect of the variant allele against 
cardiovascular diseases, specifically for myocardial infarction. Given that the results 
stem from a large randomized intervention trial, they provide a high level of evidence, 
which may be important for future nutrigenetic studies. 
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Table 1: Demographic, clinical, lifestyle characteristics and randomization to dietary 
intervention of study participants by the MLXIPL-rs3812316 polymorphism at baseline 
 
   
  CC (n=6003) CG+GG (n=1102+61) P 
Age (years) 66.9±6.2 66.8±6.4 0.623 
BMI (Kg/m2) 30±3.9 29.8±3.9 0.257 
Gender (% women)  3422(57.1) 689(59.2) 0.158 
Current smokers 834(13.9) 169(14.5) 0.688 
Type 2 diabetes 2891(48.2) 576(49.5) 0.393 
Hypertension  4969(82.8) 957(82.3) 0.687 
Systolic blood pressure (mmHg) 149.4±20.8 148.7±20.3 0.305 
Diastolic blood pressure (mmHg) 83.4±10.9 83.1±11.3 0.406 
Lipid lowering drugs, statins 2408(40.1) 463(39.8) 0.847 
Lipid lowering drugs, fibrates and others 319(5.3) 60(5.2) 0.829 
Adherence to the Mediterranean diet 8.6±2 8.7±2 0.066 
Energy intake (kcal/d) 2280.5±610.5 2258.7±585.1 0.262 
Total fat (% energy) 39.1±6.8 39.4±6.7 0.113 
Saturated fat (% energy) 10±2.3 10±2.2 0.758 
MUFA (% energy) 19.4±4.6 19.7±4.5 0.082 
PUFA (% energy) 6.2±2.1 6.3±2 0.356 
Carbohydrates (% energy) 41.9±7.1 41.6±7 0.104 
Physical activity* (kcal/d) 230.7±238.9 235.4±242.3 0.539 
Alcohol consumption (g/d) 8.4±14.3 8.5±14 0.810 
Non-drinkers 2183(36.7) 426(36.8) 0.919 
Dietary intervention groups    
 Mediterranean diet + EVOO 2070(34.5) 398(34.2) 0.915 
 Mediterranean diet + nuts 1970(32.8) 389(33.4)  
 Control group 1963(32.7) 376(32.6)   
Values are mean±SD for continuous variables and number (%) for categorical variables. BMI indicates body 
mass index; 
MUFA, Monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; EVOO, extra virgin olive oil 
P: P-value obtained in the tests for differences between genotypes 
*Leisure time physical activity 
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Table 2: Association between the MLXIPL-rs3812316 polymorphism and plasma lipids and glucose. Crude means, odds ratios (OR) for hypertriglyceridemia*, 
unadjusted and adjusted linear regression coefficients (B) 
 
         
  
MLXIPL Genotypes† 
      
 
CC 
(n=5607) CG (n=1037) GG (n=56)  Crude  Adjusted     
  Mean SD Mean SD Mean SD P1 B (95%CI) P2 B3 (95%CI) P3 P4 
Total cholesterol (mmol/l) 5.47±1.02 5.46±1.05 5.57±0.87 0.699 0.002(0.059, 0.063) 0.954 -0.04(-0.062, -0.053) 0.878 0.876 
LDL-C (mmol/l) 3.37±0.91 3.41±0.92 3.5±0.75 0.269 0.044(-0.011, 0.099) 0.116 0.038(-0.013,0.090) 0.114 0.182 
HDL-C (mmol/l) 1.39±0.37 1.4±0.35 1.55±0.41 0.004 0.020(-0,002, 0.042) 0.073 0.018(-0,002, 0.039) 0.081 0.061 
Triglycerides (mmol/l) 1.57±0.89 1.47±0.93 1.25±0.77 <0.001  -0.112(-0.166, -0.057) <0.001 -0.109(-0.162, -0.056) <0.001 <0.001 
Fasting glucose (mmol/l) 6.75±2.26 6.92±2.5 5.96±1.81 0.003 0.056(-0.085, 0.197) 0.439 0.047(-0.064, 0.159) 0.406 0.562 
Hypertriglyceridemia (%) 32.1 25.8 21.8 <0.001      
Hypertriglyceridemia, OR (95%CI) 1(ref.) 0.74(0.63-0.86) 0.59(0.31-1.12) 0.001 0.74(0.65-0.85) <0.001 0.75(0.65-0.86) <0.001 <0.001 
*Fasting triglycerides >1.7 mmol/l. P-values for triglycerides were obtained after log transformation 
Values are means and standard deviations (SD), odds ratio (OR) and 95% confidence intervals (CI) or regression coefficients (B) and 95%CI 
1: Unadjusted P values for the polymorphisms for the comparison of means or OR as categorical (three categories) 
B: Regression coefficient per-variant allele effects (genotypes coded as 0, 1 and 2 according to the number of minor alleles; additive effects) 
2: P-values obtained for the unadjusted regression coefficients considering additive effects 
3: P-values and regression coefficients obtained considering additive effects in models adjusted for sex, age, center, type 2 diabetes, BMI, lipid lowering drugs, hypoglycemic drugs, 
smoking, drinking, physical activity and total energy intake 
4: P-values for regression coefficients in model 3 additionally adjusted for blood pressure, waist circumference and family history of premature cardiovascular disease (model 4). 
†Biochemical data were available in 6700 subjects for total cholesterol, 6628 subjects for HDL-C, 6619 subjects for triglycerides, 6594 subjects for LDL-C and 6327 subjects for glucose 
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Table 3. Association between the MLXIPL-rs3812316 polymorphism* and 
hypertriglyceridemia† depending on the adherence to the Mediterranean diet 
(MedDiet) in the whole population and in relevant sub-groups‡ 
  
Adherence to MedDiet 
  
Low (<9 points) High (>=9 points) 
Strata 
  OR 95%CI OR 95%CI 
Whole population (n=6619) 
   
 MLXIPL genotypes (Model 1) 
   
 CC  1.00 (reference) 1.00 (reference) 
 G-carriers  0.88 (0.70-1.09) 0.63 (0.51-0.77) 
  P1=0.219 P1<0.001 
 MLXIPL genotypes (Model 2) 
   
 CC  1.00( reference) 1.00 (reference) 
 G-carriers  0.88 (0.70-1.10) 0.62 (0.50-0.77) 
  P2=0.248 P2<0.001 
Males (n=2829) 
   
 MLXIPL genotypes (Model 2) 
   
 CC  1.00 (reference) 1.00 (reference) 
 G-carriers  0.89 (0.63-1.27) 0.65 (0.48-0.89) 
  P2=0.519 P2=0.006 
Females (n=3790) 
   
 MLXIPL genotypes (Model 2) 
   
 CC  1.00 (reference) 1.00 (reference) 
 G-carriers  0.85 (0.64-1.14) 0.62 (0.46-0.82) 
  P2=0.273 P2=0.001 
Type-2 diabetic subjects (n=3189) 
   
 MLXIPL genotypes (Model 2) 
   
 CC  1.00 (reference) 1.00 (reference) 
 G-carriers  0.90 (0.66-1.23) 0.59 (0.44-0.79) 
  P2=0.508 P2=0.001 
Non-diabetic subjects (n=3430) 
   
 MLXIPL genotypes (Model 2)    
 CC  1.00 (reference) 1.00 (reference) 
 G-carriers  0.83 (0.63-1.14) 0.67 (0.48-0.89) 
    P2=0.247 P2=0.008 
    
*Dominant model 
†Fasting triglycerides >1.7 mmol/l; Available in 6619 subjects 
‡Odds ratios (OR) and 95% Confidence Intervals (CI) 
Model 1: Adjusted for sex, age and center 
Model 2: Additionally adjusted for type 2 diabetes, lipid lowering and hypoglycemic drugs, alcohol, 
smoking, physical activity and total energy intake 
P1: P value obtained for the genotype effect (dominant model) of the polymorphism in the 
multivariable logistic regression Model 1 stratified by MedDiet 
P2: P value obtained in Model 2 
Additional adjustment of Model 2 for blood pressure, family history of cardiovascular disease and 
waist circumference did not change the level of the statistical significance of results (P3: 0.242 for 
the whole population in the low adherence stratum and P3<0.001 in the high stratum) 
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Table 4. Association between the MLXIPL-rs3812316 polymorphism and incidence of 
cardiovascular diseases depending on the dietary intervention* groups after the 
follow-up†. Hazard ratios (HR) and 95% confidence intervals (CI) 
 
 
Intervention group 
 
Control (n=2339) 
 
Mediterranean diet* (n=4827) 
  HR 95% CI   HR 95% CI 
Total cardiovascular outcomes‡     
 MLXIPL genotypes (Model 1) 
   
 CC 1.00  (reference) 1.00  (reference) 
 G-carriers 1.04 (0.62-1.76)  0.78 (0.50-1.23) 
 P1=0.876  P1=0.292 
 MLXIPL genotypes (Model 2) 
   
 CC 1.00  (reference) 1.00  (reference) 
 G-carriers 1.03 (0.61-1.73)  0.78 (0.49-1.23) 
 P2=0.926  P1=0.290 
Myocardial Infarction      
 MLXIPL genotypes (Model 1) 
   
 CC 1.00  (reference) 1.00  (reference) 
 G-carriers 0.90 (0.35, 2.33)  0.34 (0.12, 0.93) 
 P1=0.830  P1=0.036 
 MLXIPL genotypes (Model 2) 
   
 CC 1.00  (reference) 1.00  (reference) 
 G-carriers 0.85 (0.33-2.21)  0.33 (0.12-0.91) 
 P2=0.739  P2=0.033 
Stroke      
 MLXIPL genotypes (Model 1) 
   
 CC 1.00  (reference) 1.00  (reference) 
 G-carriers 1.36 (0.73-2.59)  1.03 (0.57-1.88) 
 P1=0.346  P1=0.922 
 MLXIPL genotypes (Model 2) 
   
 CC 1.00  (reference) 1.00  (reference) 
 G-carriers 1.43 (0.75-2.72)  1.04 (0.57-1.89) 
  P2=0.279   P2=0.898 
*: Pooled group: MedDiet supplement with extra virgin olive oil (n=2468) and MedDiet plus nuts 
 (n=2359)      
†: After a median follow-up of 4.8 years (interquartile range, 2.8-5.8 years)  
‡: Major cardiovascular events (myocardial infarction, stroke and cardiovascular deaths) 
Model 1: Adjusted for sex, age, center and intervention groups    
Model 2: Additionally adjusted for type 2 diabetes, BMI, lipid lowering and hypoglycemic drugs,  
alcohol, smoking, AdMedDiet, physical activity, total energy intake and intervention group 
P1: P-value for the genotype effect (dominant) in Model 1. Cox-regression  
P2: P-value for the genotype effect in Model 2     
Further adjustments for blood pressure, waist circumference and family history of cardiovascular disease 
(Model 3) did not change the statistical significance of estimates (OR:0.35 and P3=0.040) for  
G-carriers versus CC for myocardial infarction in the MedDiet stratum    
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Figure Legends 
Figure 1: Longitudinal effect of the MLXIPL-rs3812316 polymorphism on plasma 
triglycerides. Adjusted means of triglycerides depending on the polymorphism (A) or the 
intervention group (B) at baseline, 1-y, 3-y and 5-years of follow-up in all subjects having data 
for all the four measurements (n=2,418). Adjusted means were estimated from a repeated-
measures ANOVA model with interaction terms adjusted for dietary intervention (MedDiet 
versus control), sex, age, center, BMI, type 2 diabetes, AdMedDiet, medications, smoking, 
drinking and physical activity. Adjusted P values for the overall effect of the polymorphism and 
diet are shown. P-interaction polymorphism x Diet x Time: 0.803 in the multivariable model. 
*Statistically significant adjusted P-values for the polymorphism or diet at every specific time 
point. P-values were obtained with log-transformed triglycerides. 
 
Figure 2: Cumulative myocardial infarction free-survival by MLXIPL-rs3812316 genotypes 
(CC versus G-carriers) in the MedDiet intervention group (n=4,827). Cox regression model 
with outcome of myocardial infarction onset and the polymorphism adjusted by sex, age, center, 
type 2 diabetes, adherence to MedDiet, BMI, lipid lowering drugs, hypolipemic drugs, alcohol, 
smoking, physical activity, total energy intake and intervention group. HR estimated in the 
multivariable model. 
1SUPPLEMENTAL MATERIAL
SUPPLEMENTAL METHODS
Subject characteristics
Eligible subjects were community-dwelling people (55-80 years for men; 60-80 years for women)
who fulfilled at least one of two criteria: type 2 diabetes1-3 or more cardiovascular risk factors
(hypertension, dyslipidemia, body mass index [BMI] ≥25 kg/m2, current smoking, or a family history of
premature cardiovascular disease2. Exclusion criteria included a personal history of cardiovascular
disease, any severe chronic illness, and drug or alcohol addiction2.
The Institutional Review Board of each participating center approved the study protocol, and all
participants provided written informed consent.
Demographic, clinical, anthropometric and dietary measurements
The baseline examination included assessment of standard cardiovascular risk factors,
medication use, socio-demographic factors and lifestyle variables2.
Food consumption was determined by a validated semi-quantitative food frequency questionnaire3.
Physical activity was estimated by the validated Minnesota Leisure-Time Physical Activity Questionnaire
as previously reported2. Weight and height were measured with calibrated scales and a wall-mounted
stadiometer, respectively2.
Outcome ascertainment
The primary endpoint was the occurrence of the first major cardiovascular event and comprised
myocardial infarction, stroke or cardiovascular death2. We used four sources of information to identify
end-points: 1) direct participant contact; 2) family physicians; 3) yearly review of medical records; and 4)
consultation of the National Death Index. Medical records related to end-points were examined by the
end-point adjudication committee, whose members were blind to treatment allocation. End-points
confirmed by the committee occurring between October 1, 2003, and December 1, 2010 were included
in the analyses.
Supplemental Methods References
1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care
2008;31:S55–S60.
2. Martínez-González MA, Corella D, Salas-Salvadó J, Ros E, Covas MI, Fiol M, et al. Cohort Profile:
Design and methods of the PREDIMED study. Int J Epidemiol. 2012;41:377-385.
3. Fernández-Ballart JD, Piñol JL, Zazpe I, Corella D, Carrasco P, Toledo E, et al. Relative validity of
a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain.
Br J Nutr. 2010;103:1808-1816.
2Table S1. Quantitative Score of Adherence to the Mediterranean Diet (14-items)
Foods and frequency of consumption Criteria for 1 point*
1 Do you use olive oil as main culinary fat? Yes
2 How much olive oil do you consume in a given day (including oil used for frying, salads, out of house
meals, etc.)?
4 or more tablespoons
3 How many vegetable servings do you consume per day?
(1 serving = 200g - consider side dishes as 1/2 serving)
2 or more (at least 1 portion raw
    or as salad)
4 How many fruit units (including natural fruit juices) do you consume per day? 3 or more
5 How many servings of red meat, hamburger, or meat products (ham, sausage, etc.) do you
consume per day? (1 serving = 100-150 g)
Less than 1
6 How many servings of butter, margarine, or cream do you consume per day? (1 serving = 12 g) Less than 1
7 How many sweet/carbonated beverages do you drink per day? Less than 1
8 How much wine do you drink per week? 7 or more glasses
9 How many servings of legumes do you consume per week?
(1 serving = 150 g)
3 or more
10 How many servings of fish or shellfish do you consume per week?
 (1 serving: 100-150 g fish, or 4-5 units or 200 g shellfish)
3 or more
11 How many times per week do you consume commercial sweets or pastries (not homemade), such
as cakes, cookies, biscuits, or custard?
Less than 3
12 How many servings of nuts (including peanuts) do you consume per week?
(1 serving = 30 g)
3 or more
13 Do you preferentially consume chicken, turkey or rabbit meat instead of veal, pork, hamburger or
sausage?
Yes
14 How many times per week do you consume vegetables, pasta, rice, or other dishes seasoned with
sofrito (sauce made with tomato and onion, leek, or garlic, simmered with olive oil)?     2 or more
 * 0 points if these criteria are not met.
3Table S2: Demographic, clinical, lifestyle and genetics characteristics of the study participants
at baseline according to the dietary intervention groups
MedDiet with EVOO
(n=2468)
MedDiet with Nuts
(n=2359)
Control group
(n=2339)
Age (years) 66.9 ± 6.2 66.6 ± 6.1 67.3 ± 6.3
BMI (Kg/m2) 29.9 ± 3.7 29.7 ± 3.8 30.2 ± 4.0
Waist circumference (cm) 100.2 ± 10.4 100.2 ± 10.5 100.8 ± 10.9
Female sex* : n, % 1447 (58.6) 1269 (53.8) 1395 (59.6)
Current smokers: n, % 345 (14.7) 337 (14.3) 321 (13.7)
Type 2 diabetes: n, % 1236 (50.1) 1099 (46.6) 1132 (48.4)
Hypertension: n, % 2022 (81.9) 1947 (82.6) 1957 (83.7)
Lipid lowering drugs, statins: n, % 1011 (41.0) 922 (39.1) 938 (40.1)
Lipid lowering drugs, fibrates and
others: n, %
118 (4.8) 142 (6.0) 119 (5.1)
MLXIPL-rs3812316 genotypes: n, %
   CC 2070 (83.9) 1970 (83.5) 1963 (83.9)
   G-carriers 398 (16.2) 389 (16.5) 376 (16.1)
Energy intake (kcal/d) 2288 ± 608 2317 ± 607 2224 ± 600
Total fat (% energy) 39.2 ± 6.9 39.4 ± 6.5 39.0 ± 6.9
Saturated fat (% energy) 10.0 ± 2.2 10.0 ± 2.2 10.0 ± 2.3
MUFA (% energy) 19.6 ± 4.6 19.5 ± 4.3 19.3 ± 4.8
Proteins (% energy) 16.6 ± 2.9 16.5 ± 2.7 16.6 ± 2.9
Carbohydrates (% energy) 41.8 ± 7.3 41,6 ± 7.0 42.3 ± 7.2
Adherence to the MedDiet (points) 8.7 ± 2.0 8.7 ± 2.0 8.4 ± 2.0
Alcohol consumption (g/d) 8.6 ± 14.4 9.2 ± 15.0 7.5 ± 13.2
Physical activity (kcal/d) 232 ± 233 248 ± 246 215 ± 240
Values are mean±SD for continuous variables and number (%) for categorical variables. BMI indicates body mass
index; MUFA, Monounsaturated fatty acids; EVOO, extra virgin olive oil; MedDiet, Mediterranean diet.
4Figure S1. Adjusted means of fasting triglyceride concentrations at baseline depending on
the MLXIPL-rs3812316 polymorphism and the level of adherence to the Mediterranean Diet
(AdMedDiet). Means were adjusted for age, sex, center, BMI, type 2 diabetes, medications, total
energy intake, physical activity, smoking and drinking.  P values were obtained for the comparison
of means between MLXIPL-rs3812316 genotypes depending on the strata of AdMedDiet (Low and
High). Triglycerides were log-transformed for statistical analyses. Error bars: SE of means
(n=6619).
1.5
1.6
1.7
1.8
1.9
GG C carriers GG C carriers
Low AdMedDiet High AdMedDiet
Tr
ig
ly
ce
rid
es
(m
m
ol
/l)
.A
dj
us
te
d
m
ea
ns
P=0.102
P<0.001
CC G-carriers CC G-carriers
5Figure S2: Longitudinal effect of the MLXIPL-rs3812316 polymorphism on plasma
triglycerides. Adjusted means of triglycerides depending on the polymorphism (dominant model)
and dietary intervention group at baseline, 1-y, 3-y and 5-years of follow-up in all subjects having
data for all the four measurements (n=2,418). Adjusted means were estimated from a repeated-
measures ANOVA model with interaction terms adjusted for dietary intervention (MedDiet versus
control), sex, age, center, BMI, type 2 diabetes, AdMedDiet, medications, smoking, drinking and
physical activity. Adjusted P values for the overall effect of the polymorphism diet and for the
interaction among the polymorphism x Diet x Time, were obtained in the multivariable model. *P
value for lineal trend between the four combined categories genotype and diet at 5-year follow-up.
P-values were obtained with log-transformed triglycerides.
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6Figure S3: Longitudinal effect of the MLXIPL-rs3812316 polymorphism on hypertriglyceridemia (triglycerides >1.7mmol/L). Prevalence of hypertriglyceridemia
depending on the polymorphism (dominant model) and dietary intervention group at baseline, 1-y, 3-y and 5-years of follow-up in all subjects having data for all the four
measurements (n=2,418). OR for triglyceridemia after 5-year follow-up were estimated. CC subjects in the control group were considered the reference category. Crude and
multivariable adjusted models were fitter. Models were adjusted for sex, age, center, BMI, type 2 diabetes, AdMedDiet, medications, smoking, drinking and physical activity.
7Table S3. Effect of the intervention with Mediterranean diet* on the incidence
of cardiovascular diseases** stratified by the MLXIPL -rs3812316 polymorphism.
Hazard ratios (HR) and 95% confidence intervals (CI)
HR 95% CI HR 95% CI
Total cardiovascular outcomes***
  Intervention group (Model 1)
     Control group 1.00 (reference) 1.00 (reference)
     Mediterranean diet 0.68 (0.52-0.90) 0.52 (0.27-0.99)
  Intervention group (Model 2)
     Control group 1.00 (reference) 1.00 (reference)
     Mediterranean diet 0.69 (0.52-0.91) 0.51 (0.26-0.99)
Myocardial Infarction
  Intervention group (Model 1)
     Control group 1.00 (reference) 1.00 (reference)
     Mediterranean diet 0.84 (0.54-1.31) 0.29 (0.08-1.10)
  Intervention group (Model 2)
     Control group 1.00 (reference) 1.00 (reference)
     Mediterranean diet 0.84 (0.54-1.32) 0.24 (0.06-0.96)
Stroke
  Intervention group (Model 1)
     Control group 1.00 (reference) 1.00 (reference)
     Mediterranean diet 0.58 (0.39-0.85) 0.48 (0.21-1.07)
  Intervention group (Model 2)
     Control group 1.00 (reference) 1.00 (reference)
     Mediterranean diet 0.58 (0.39-0.86) 0.51 (0.23-1.15)
*: Pooled group: Mediterranean diet supplemented with extra virgin olive oil (n=2468) and Mediterranean diet
supplemented with nuts (n=2359)
**: After a median follow-up of 4.8 years (interquartile range, 2.8 to 5.8 years)
***: Major cardiovascular events (myocardial infarction, stroke and cardiovascular deaths)
Model 1:  Adjusted for sex, age and center
Model 2: Adjusted for sex, age, center, type 2 diabetes, BMI, lipid lowering drugs, hypoglycemic drugs,
drinking, smoking, adherence to MedDiet, physical activity and total energy intake
P1: P value obtained for diet effect in multivariable Cox regression Model 1
P2: P value obtained for diet effect in multivariable Cox regression Model 2
Further adjustment of Model 2 for blood pressure, family history of cardiovascular disease, waist
circumference or lipids did not change the statistical significance of the estimates
      P1=0.007 P1=0.046
      P2=0.008 P2=0.045
MLXIPL -rs3812316 genotypes
CC (n=6003) G-carriers (n=1163)
      P2=0.007 P2=0.105
P2=0.043      P2=0.447
      P1=0.005 P1=0.069
      P1=0.440 P1=0.070
8Table S4. Association between the MLXIPL -rs3812316 polymorphism and incidence
of myocardial infarction depending on the dietary intervention* groups after the
follow-up**. Incidence rates, hazard ratios (HR) and 95% confidence intervals (CI)
Myocardial infarction
Groups (Model 1)
     CC /control group 1.00 (reference)
     G-carriers/ control group 0.90 (0.35-2.33)
     CC /MedDiet group 0.82 (0.53-1.27)
     G-carriers/ MedDiet group 0.28 (0.10-0.79)
   MLXIPL genotypes (Model 2)
     CC 1.00 (reference)
     G-carriers 0.85 (0.33-2.21)
     CC /MedDiet group 0.83 (0.55-1.28)
     G-carriers/ MedDiet group 0.29 (0.11-0.80)
*: Pooled group: Mediterranean diet supplement with extra virgin olive oil (n=2468) and Mediterranean diet
supplemented with nuts (n=2359) vs control group (n=2339)
**: After a median follow-up of 4.8 years (interquartile range, 2.8 to 5.8 years)
***: Crude incedence rates expressed per 1000 person-y follow-up
Model 1:  Adjusted for sex, age, center and intervention groups
Model 2:  Adjusted for sex, age, center, type 2 diabetes,BMI, lipid lowering drugs, hypoglycemic drugs,
alcohol, smoking, AdMedDiet, physical activity, total energy intake and intervention group
P1: P-value for the genotype effect (dominant) in Model 1
P2: P-value for the genotype effect in Model 2
3.82
3.33
1.10
3.30
3.82
3.33
3.30
1.10
Incidence rate*** HR and 95% CI
